- December 2024Board Governance in the Age of AI: Navigating Risks of Note-Taking Tools
- December 2024Navigating AI and Fiduciary Duties: 10 Key Questions for Your Organization
- December 2024Letter from the Editor
- December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
- November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
- Destination Skiing And The DOJ's Mountain Merger Challenge
- Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
- Third QuarterGeneric Launches
- Third QuarterANDA Approvals
- Third QuarterANDA Litigation Settlements
- Third QuarterNew ANDA Cases
- September 2024Meet Our New Partner and Trial Advocacy Seminar Keynote Speaker: B. Todd Jones
- September 2024The Wealth Dispute Navigator: Which Profile Are You?
- Astellas Pharma, Inc. v. Sandoz Inc.
- September 18, 2024Astellas Pharma, Inc. v. Sandoz Inc.
- September 2024Q&A with Alan Harter, Founder of Pactolus Private Wealth Management
- September 9, 2024Purdue Pharma L.P v. Accord Healthcare Inc.
- September 4, 2024Exeltis USA, Inc. v. Lupin Ltd.
- Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
- August 2024Recruiting & Retaining Diverse Attorneys: Building an Inclusive Legal Profession
- Prior Art Takeaways From Fed. Circ. Public Disclosure Ruling
- August 13, 2024Allergan USA, Inc. v. MSN Labs. Private Ltd.
- Novartis Pharms. Corp. v. Becerra
- Playing Dungeons & Dragons Makes Me A Better Lawyer
- Novartis Pharms. Corp. v. Hetero USA Inc.
- Novartis Pharms. Corp. v. MSN Pharms. Inc.
- Pacira Pharms., Inc. v. eVenus Pharms. Labs., Inc.
- August 7, 2024Making a Case for Trade Secret Misappropriation in the US
- Otsuka Pharm. Co., Ltd. v. Lupin Ltd.
- Navigating Copyright Act Section 117 in Software Licensing and Litigation
- "Same as it Ever Was": Why Audio-Video Recordings in and of Trial Court Proceedings Should Not Change the Standard of Appellate Review
- Allergan Holdings Unlimited Co. v. MSN Labs. Private Ltd.
- 2024 Bulletin - Second QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2024 Q2
- Making The Whole Truth Public
- Litigation Perspective: Strategies for Licensing Software that Leverages Artificial Intelligence
- June/July 2024A Dive Into Intellectual Property Liability For E-Commerce Platforms
- Amarin Pharma, Inc. v. Hikma Pharms. USA Inc.
- Second QuarterANDA Litigation Settlements
- June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
- June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
- June 2024California's Sustainable Insurance Strategy: Balancing Innovation with Industry Challenges
- June 2024A Magnifying Glass on the Notice Prejudice Standard in Massachusetts for Excess Insurers
- June 2024AI’s Impact on Property Insurance Coverage
- June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
- September 2024The Wealth Dispute Navigator: Which Profile Are You?
- June 2024Q&A With Anne Paape, Managing Director and Senior Fiduciary Counsel at Cresset
- June 2024Estate Planning to Protect Generational Wealth Transfers: Lessons from The Gilded Age
- Three Alternatives to the USPTO's Terminal Disclaimer Proposal
- Teva Branded Pharm. Products R&D, Inc. v. Amneal Pharms. of NY, LLC
- June 2024Access to Justice Is a Right, Not a Privilege
- May 2024Passing the Buck: The Perils of Oklahoma v. Castro-Huerta
- Warzone Clash: When Does a Video Game Title Cross the Line Into Trademark Infringement?
- May 2024Q&A with Anthony Froio
- April 30, 2024A World Without Non-Competes: Protecting Confidential Information and Trade Secrets Following the FTC's Ban
- Pharmacyclics LLC v. Alvogen Pine Brook LLC
- 2024 Bulletin - First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2024 Q1
- Salix Pharms., Ltd. v. Norwich Pharms. Inc.
- Second QuarterGeneric Launches
- Second QuarterNew ANDA Cases
- Janssen Pharms., Inc. v. Teva Pharms. USA, Inc.
- April 1, 2024Janssen Pharms., Inc. v. Tolmar, Inc.
- Second QuarterANDA Approvals
- March 2024e-Commerce: Pitfalls and Protections
- Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
- ‘In re Cellect’:
- Mallinckrodt plc v. Airgas Therapeutics LLC
- How Many Cases Have You Tried to a Verdict?
- March 2024Sellers of a Business: Know Thyself.
- March 2024Unintended Consequences: Don’t Forget the Litigation Risks When Getting a Deal Done
- March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Cotext
- March 8, 2024UCB, Inc. v. Mylan Techs. Inc.
- March 5, 2024Genentech, Inc. v. Sandoz, Inc.
- March 2024Tony Schrank: Advocating for Justice Beyond the Courtroom
- Janssen Pharms., Inc. v. Tolmar, Inc.
- Endo Par Innovation Co.
v. BPI Labs, LLC - First QuarterANDA Litigation Settlements
- January 2024Entitlement to Priority in the European Patent Office
- Novartis Pharms. Corp. v. Mylan Pharms. Inc.
- Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH
- January 2024Navigating the Legal Landscape: Generative AI and Copyright Law
- 2023 Bulletin - Fourth QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2023 Q4
- February 8, 2024Behind the numbers: 2023 patent litigation trends in the Western District of Texas
- January 2024Crack the Code: Evaluating Cyber Claim Exposure
- January 2024Considerations for D&O Insurance in light of the Changing Diversity, Equity, and Inclusion (DEI) Legal Landscape
- January 2024The Weight of Words
- First QuarterNew ANDA Cases
- January 2024The Robins Kaplan Insurance Insight June 2024
- First QuarterGeneric Launches
- January 3, 2024Navigating Class Actions After Papa John's Settlement Denial
- December 28, 2023Data Shows Most SEP Holders Send Pre-Suit Demand Letters - For Good Reason
- First QuarterANDA Approvals
- December 29, 2023Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
